このエントリーをはてなブックマークに追加
ID 48659
本文ファイル
著者
Sakamoto, Shinjiro 大学院医歯薬保健学研究院 広大研究者総覧
Yoshitomi, Munehiro
Yutani, Shigeru
Terazaki, Yasuhiro
Yoshiyama, Koichi
Ioji, Tetsuya
Matsueda, Satoko
Yamada, Akira
Takamori, Shinzo
Itoh, Kyogo
Hattori, Noboru 大学院医歯薬保健学研究院(医) 広大研究者総覧
Kohno, Nobuoki 大学院医歯薬保健学研究院(医)
Sasada, Tetsuro
キーワード
ARG1
biomarker
MMP-9
MPO
multivariate Cox regression analysis
personalized peptide vaccine
抄録(英)
Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and inhibitory cytokine TGFβ in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer patients. In biliary tract cancer (n=25), multivariate Cox regression analysis demonstrated that patients with higher plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) = 4.637, 95% confidence interval (CI) = 1.670 - 12.877, P = 0.003], whereas MPO, ARG1, or TGFβ levels were not correlated with OS. Similarly, patients with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced cancers, including non-small cell lung cancer (n=32, P = 0.037 by log-rank test), and pancreatic cancer (n=41, P = 0.042 by log-rank test). Taken together, plasma MMP-9 levels before vaccination might be potentially useful as a biomarker for selecting advanced cancer patients who would benefit from PPV.
内容記述
This study was supported by a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan; a research program of the Regional Innovation Cluster Program of the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Kurozumi Medical Foundation.
掲載誌名
Human Vaccines & Immunotherapeutics
11巻
12号
開始ページ
2784
終了ページ
2789
出版年月日
2015-12-23
出版者
Taylor & Francis Group, LLC
ISSN
2164-5515
2164-554X
出版者DOI
PubMedID
言語
英語
NII資源タイプ
学術雑誌論文
広大資料タイプ
学術雑誌論文
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
権利情報
© Cancer Vaccine Center, Kurume University. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properlycited. Themoral rights of the named author(s) have been assertted.
関連情報URL
部局名
医歯薬保健学研究科